Recently, increasing clinical and experimental studies have shown that the expression of NLRP3 inflammasome components (NLRP3, caspase-1, and ASC) was remarkably increased in the patients with NAFLD and in the mice model (Wree et al., 2014; Mitsuyoshi et al., 2017; Gaul et al., 2021). This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.